|
| 37801329 | Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. | Clin Cancer Res | 2024 |
| 37801329 | Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. | Clin Cancer Res | 2024 |
| 36288547 | Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. | J Clin Oncol | 2023 |
| 36288547 | Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. | J Clin Oncol | 2023 |
| 36136304 | Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. | Clin Cancer Res | 2023 |
| 37274265 | Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage <i>RET</i> fusion-positive non-small cell lung cancer. | Front Oncol | 2023 |
| 37272535 | Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC. | N Engl J Med | 2023 |
| 37023987 | Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 37270692 | Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Non-Small-Cell Lung Cancer. | J Clin Oncol | 2023 |
| 36872181 | Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. | Clin Lung Cancer | 2023 |
| 36996322 | Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers. | Clin Cancer Res | 2023 |
| 37236398 | Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. | J Thorac Oncol | 2023 |
| 36923158 | Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. | JTO Clin Res Rep | 2023 |
| 36534268 | Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. | Target Oncol | 2023 |
| 36725084 | First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. | J Immunother Cancer | 2023 |
| 36720083 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. | J Clin Oncol | 2023 |
| 37023987 | Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 37274265 | Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage <i>RET</i> fusion-positive non-small cell lung cancer. | Front Oncol | 2023 |
| 37272535 | Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC. | N Engl J Med | 2023 |
| 37270692 | Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Non-Small-Cell Lung Cancer. | J Clin Oncol | 2023 |
| 37236398 | Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. | J Thorac Oncol | 2023 |
| 36996322 | Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers. | Clin Cancer Res | 2023 |
| 36725084 | First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. | J Immunother Cancer | 2023 |
| 36923158 | Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. | JTO Clin Res Rep | 2023 |
| 36720083 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. | J Clin Oncol | 2023 |
| 36872181 | Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. | Clin Lung Cancer | 2023 |
| 36534268 | Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. | Target Oncol | 2023 |
| 36136304 | Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. | Clin Cancer Res | 2023 |
| 34740861 | Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. | J Thorac Oncol | 2022 |
| 36166003 | Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. | Clin Cancer Res | 2022 |
| 35699623 | Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 35950566 | LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancer. | Future Oncol | 2022 |
| 35719865 | Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report. | JTO Clin Res Rep | 2022 |
| 36426286 | The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. | JTO Clin Res Rep | 2022 |
| 35400584 | A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. | Clin Lung Cancer | 2022 |
| 35302585 | ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study. | Clin Cancer Res | 2022 |
| 34740861 | Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. | J Thorac Oncol | 2022 |
| 34843401 | Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. | J Clin Oncol | 2022 |
| 35012927 | Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. | Clin Cancer Res | 2022 |
| 35324247 | Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study. | Health Psychol | 2022 |
| 34748398 | Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. | JCO Oncol Pract | 2022 |
| 35400584 | A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. | Clin Lung Cancer | 2022 |
| 35699623 | Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 35719865 | Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report. | JTO Clin Res Rep | 2022 |
| 36426286 | The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. | JTO Clin Res Rep | 2022 |
| 36166003 | Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. | Clin Cancer Res | 2022 |
| 35950566 | LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancer. | Future Oncol | 2022 |
| 35012927 | Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. | Clin Cancer Res | 2022 |
| 35302585 | ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study. | Clin Cancer Res | 2022 |
| 35324247 | Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study. | Health Psychol | 2022 |